Opendata, web and dolomites

Hyalcis

Hyaluronic-Cisplatin Film for Implant in Malignant Mesothelioma Recurrence

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Hyalcis project word cloud

Explore the words cloud of the Hyalcis project. It provides you a very rough idea of what is the project "Hyalcis" about.

north    die    registration    diagnose    biodegradable    film    cancer    worldwide    months    obtaining    pleura    prevention    hyalcis    form    full    difficult    australia    planning    feasibility    tests    linked    benefits    hydrophilic    asbestos    surgery    introduces    resistant    industrialization    25    company    toxicity    proposing    reaching    solution    qualified    2016    sufficiently    limiting    situ    polymeric    feedback    agency    financial    aggressive    business    plan    intrapleural    disease    effectiveness    provider    tumor    cisplatin    people    confirmed    local    safety    combined    concentrations    districts    recovery    achievable    years    plumestars    mesothelioma    animals    anticancer    capture    prolonged    curative    malignant    recurrence    market    medicinal    adhering    rare    precisely    preparation    release    epithelial    residual    treat    medical    japan    treatment    successfully    43    thin    efficiency    designation    protection    construction    pleural    innovative    flexible    extremely    satisfactory    surfaces    entitles    industry    competitors    200m    drug    america    orphan    mesothelial    opportunity   

Project "Hyalcis" data sheet

The following table provides information about the project.

Coordinator
PLUMESTARS SRL 

Organization address
address: STRADA INZANI 1
city: PARMA PR
postcode: 43124
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.plumestars.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PLUMESTARS SRL IT (PARMA PR) coordinator 50˙000.00

Map

 Project objective

Hyalcis is a novel medicinal product, based on an innovative biodegradable film technology, for the prevention of the recurrence after surgery of malignant pleural mesothelioma. The proposing company, PlumeStars s.r.l., has successfully applied to the European Medical Agency, obtaining in 2016 the orphan designation for Hyalcis. This entitles PlumeStars as unique provider of the product, i.e, a polymeric film to treat pleura mesothelioma, for which there are no satisfactory curative methods. To capture this unique business opportunity, the Phase 1 project will develop a detailed Business Plan achievable within 6 months, including technical feasibility assessment based on qualified feedback and requirements from users, detailed market analysis, competitors analysis, industrialization planning, key partnerships preparation, knowledge protection and financial planning. Mesothelioma is a very aggressive form of cancer linked to asbestos use in construction and industry. It is difficult to diagnose, highly resistant to treatment and full recovery is extremely rare. Over 43,000 people die every year worldwide for the disease and that 10,000 new cases of mesothelioma combined in Europe, North America, Japan and Australia occur each year. The solution developed by PlumeStars is a hydrophilic, thin and flexible film, sufficiently resistant to be applied intrapleural or in other districts, adhering to the mesothelial or epithelial surfaces. The cisplatin release from the film is prolonged providing high local concentrations of anticancer drug, precisely in situ where the residual tumor could develop. This introduces significant benefits in terms of effectiveness, limiting tumor recurrence, low toxicity and increased safety and efficiency. This benefits have been confirmed in the tests already carried out on animals. PlumeStars aims at reaching 25% of the 200M€/year target market in 5 years, including 2 years for industrialization and registration.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYALCIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYALCIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More